Clinical Trial Update: A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

View source ↗

Summary

A long-term extension study for participants previously treated with EB-101 for recessive dystrophic epidermolysis bullosa is enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• EB-101

Snippet

Sponsor: Abeona Therapeutics, Inc | Conditions: RDEB | Status: ENROLLING_BY_INVITATION